PrecisemAb Biotech
PrecisemAb creates precise antibody treatment, giving patients the safest and most effective therapy with innovative Antibody Lock.
Fundraising Status
Seed Round
Fundraising Target: 4M
Schedule: 2024 Q2
Revenue (USD)
2022: 3.6K
2023 Target: 300K
Competitors
CytomX
Adagene
Xilio Therapeutics
US Objective
Expected Results
Fundraising
Business engagement
Co-development Partners
Specific Organizations/VCs to Engage
VCs: Y Combinator, a16z, 500 Global
Strategic partners: ADC Biotech companies and Pharma. Ex: Eli Lily, Merck, Johnson & Johnson, Amgen, Bristol Myers Squibb (BMS)
Company Details
Short description
Founded in 2021, PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. Through (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials.
Core Technology
Antibody drugs lead to serious side effects because they cannot distinguish disease tissue from normal tissue, which limits their application and clinical trial failure. Universal Antibody Lock is a masking structure on the binding site of an antibody that allows antibody drugs to take effect only in diseased areas, solving systemic toxicity, and making antibody treatment safe and effective. PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1.
PrecisemAb Executive Summary_202303 - LiChen Yen.pdf